Tebentafusp (also known as IMCgp100) is a bispecific protein drug that helps the immune system recognize and fight cancer cells. It is specifically designed for patients who have a certain genetic marker called HLA-A*02:01 and are diagnosed with uveal melanoma (a type of eye cancer). This medication works by connecting immune cells to cancer cells, enabling the immune system to better target and destroy the cancer. It is given to patients after their initial cancer treatment to help prevent the cancer from coming back.

Observation is the standard approach where patients are regularly monitored by their healthcare team without receiving active treatment. During observation, doctors perform regular check-ups and tests to watch for any signs that the cancer might be returning.

Uveal Melanoma – A rare type of cancer that develops in the uvea, the middle layer of the eye that contains blood vessels and pigment cells. The disease begins when pigment-producing cells called melanocytes in the uvea start growing abnormally and form a tumor. These tumors typically develop in one eye and can affect any part of the uveal tract, including the iris, ciliary body, or choroid. As the tumor grows, it can cause changes in vision or visible changes to the eye’s appearance. The disease can spread from its original location to other parts of the body through the bloodstream.